biossil is an AI native biopharma company based in Toronto.

It is advancing 11 Phase 2 & 3 programs in life-threatening indications with urgent unmet needs.

Active trials include Sickle Cell Disease, Idiopathic Pulmonary Fibrosis, Glioblastoma, Breast Cancer, and Alzheimer’s Disease.

This year trials will additionally launch in Hereditary Xerocytosis, Cisplatin-associated nephrotoxicity, BCC/SCC, MPS VI, GI-Acute Radiation Syndrome, and Premature Ovarian Failure.

Clinical stage programs in development beyond 2026 include Portal Hypertension, Radiation Dermatitis, Necrotizing Soft Tissue Infection, Vaso-Occlusive Crises and Diabetic Cardiomyopathy.

This work is supported by OpenAI and Founders Fund, among others. It is led by Alexander I. Mosa (MD PhD) and Anthony Mouchantaf (JD MBA).

For more information, contact info@biossil.ai

For peer-reviewed data about our current pipeline:
Anderson, 2025 (a); Anderson 2025 (b); Anderson 2025 (c); Pulliam, 2025; Wagner 2024; Walker 2024; Uzomah, 2024; Dunlap 2024; Anderson, 2024; Januzzi, 2024; Yao, 2024; Dampier, 2023; Mosa, 2023; Campo, 2023; Tuyaa-Boutsugue, 2023; Mapuskar, 2023; Greco, 2023; Gopal, 2023; Hausmann, 2023; Guffon, 2022; Anderson, 2022; Giralt, 2022; Ataga, 2021; Nayak, 2021; Brakenridge, 2021; Ko, 2021; Hickerson, 2021; Sisch, 2021; Coyle, 2021; Gopal, 2021; Tammara, 2020; Dampier, 2020; Bulgar, 2020; Mosa, 2020(a); Mosa, 2020(b); Entchev, 2020; Jin, 2019; Edgar, 2019; Anderson, 2019; Anderson, 2018; Morikis, 2017; Tammara, 2017; Riviera, 2017; Organ, 2017; Telen, 2015; Ramachandran, 2015; Urowtiz, 2015; Bulger, 2014; Mirzoeva, 2014; Sthoeger, 2013; Chang, 2010; Price, 2009; Alper, 2008; Sela, 2008; Myers, 2008; Elmann, 2007; Upreti, 2006; Toomey, 2006; Arad, 2000.